Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Difference between revisions of "Template:SUIT-016"

From Bioblast
Line 9: Line 9:
|-
|-
| 1OctM
| 1OctM
| [[OctM]]<sub>''L''</sub>
| [[OctM]]<sub>''[[L]]''</sub>
| [[Fatty acid oxidation pathway control state| F(N)]]
| [[Fatty acid oxidation pathway control state| F(N)]]
| FAO
| CETF
| OctM<sub>''L''</sub> or OctM_L: Octanoylcarnitine & low malate, N-LEAK respiration, N<sub>''L''</sub>
| 1OctM


{{Template:SUIT F}} {{Template:SUIT M low}} {{Template: SUIT L(n)}}
*{{Template:SUIT F}}
*{{Template:SUIT M low}}
*{{Template: SUIT L(n)}}


|-
|-
| 2D
| 2D
| [[OctM]]<sub>''P''</sub>
| [[OctM]]<sub>''[[OXPHOS|P]]''</sub>
| [[Fatty acid oxidation pathway control state| F(N)]]
| [[Fatty acid oxidation pathway control state| F(N)]]
| FAO
| CETF
| 1OCtM;2D
| 1OctM;2D


{{Template:SUIT F}} {{Template:SUIT M low}} {{Template:SUIT OXPHOS}}
*{{Template:SUIT F}}
*{{Template:SUIT M low}}
*{{Template:SUIT OXPHOS}}


|-
|-
| 3G
| 3G
| [[OctGM]]c<sub>''P''</sub>
| [[OctGM]]<sub>''[[OXPHOS|P]]''</sub>
| [[FN]]
| [[FN]]
| CETF&I
| CETF&I
| 1OCtM;2D;3G
| 1OctM;2D;3G


{{Template:SUIT F}} & {{Template:SUIT N}} {{Template:SUIT FN}} {{Template:SUIT OXPHOS}} Β 
*{{Template:SUIT F}} & {{Template:SUIT N}}
*{{Template:SUIT FN}}
*{{Template:SUIT OXPHOS}} Β 


|-
|-
| 4S
| 4S
| [[OctGMS]]<sub>''P''</sub>
| [[OctGMS]]<sub>''[[OXPHOS|P]]''</sub>
| [[FNS]]
| [[FNS]]
| CETF&CI&II
| CETF&CI&II
| 1OCtM;2D;3G;4S
| 1OctM;2D;3G;4S


{{Template:SUIT NS}} {{Template:SUIT F}} {{Template:SUIT OXPHOS}} Β 
*{{Template:SUIT F}} & {{Template:SUIT N}} & {{Template:SUIT S}}
*{{Template:SUIT FNS}}
*{{Template:SUIT OXPHOS}} Β 


|-
|-
| 5Rot
| 5Rot
| [[S]]<sub>''P''</sub>
| [[S]]<sub>''[[OXPHOS|P]]''</sub>
| [[S]]
| [[S]]
| CII
| CII
| 1OCtM;2D;3G;4S;5Rot
| 1OctM;2D;3G;4S;5Rot


{{Template:SUIT Rot}} {{Template:SUIT S}} {{Template:SUIT OXPHOS}}
*{{Template:SUIT Rot}}
*{{Template:SUIT S}}
*{{Template:SUIT OXPHOS}}


|-
|-
| 6Omy
| 6Omy
| [[S]]<sub>''L''</sub>
| [[S]]<sub>''[[L]]''</sub>
| [[S]]
| [[S]]
| CII
| CII
| 1OCtM;2D;3G;4S;5Rot;6Omy
| 1OctM;2D;3G;4S;5Rot;6Omy


{{Template:SUIT L n}} {{Template:SUIT S}}
*{{Template:SUIT S}}
*{{Template:SUIT L(n)}}


|-
|-
| 7U
| 7U
| [[S]]<sub>''E''</sub>
| [[S]]<sub>''[[E]]''</sub>
| [[S]]
| [[S]]
| CII
| CII
| 1OCtM;2D;3G;4S;5Rot;6Omy;7U
| 1OctM;2D;3G;4S;5Rot;6Omy;7U


{{Template:SUIT U*}} {{Template:SUIT S}} {{Template:SUIT ET}}
*{{Template:SUIT S}}
*{{Template:SUIT U*}}
*{{Template:SUIT ET}}


|-
| 8Ama
| [[ROX]]
|
|
| 1OctM;2D;3G;4S;5Rot;6Omy;7U;8Ama
*{{Template:SUIT Ama}}


|}
|}
{{Template:Keywords in SUIT protocols}}
{{Template:Keywords in SUIT protocols}}

Revision as of 17:11, 28 January 2019

MitoPedia: SUIT

Steps and respiratory states

1OctM;2D;3G;4S;5Rot;6Omy;7U-.png


Step State Pathway Q-junction Comment - Events (E) and Marks (M)
1OctM OctML F(N) CETF 1OctM
  • Respiratory stimulation of the FAO-pathway, F, by fatty acid, FA, in the presence of malate, M. Malate is a type N substrate (N), required for the F-pathway. The FA concentration has to be optimized to saturate the F-pathway, without inhibiting or uncoupling respiration.
  • Low concentration of malate, typically 0.1 mM, does not saturate the N-pathway; but saturates the F-pathway.
  • Non-phosphorylating resting state (LEAK state); LEAK respiration L(n) in the absence of ADP, ATP, AMP (no adenylates).
2D OctMP F(N) CETF 1OctM;2D
  • Respiratory stimulation of the FAO-pathway, F, by fatty acid, FA, in the presence of malate, M. Malate is a type N substrate (N), required for the F-pathway. The FA concentration has to be optimized to saturate the F-pathway, without inhibiting or uncoupling respiration.
  • Low concentration of malate, typically 0.1 mM, does not saturate the N-pathway; but saturates the F-pathway.
  • OXPHOS capacity P (with saturating [ADP]), active OXPHOS state.
3G OctGMP FN CETF&I 1OctM;2D;3G
  • Respiratory stimulation of the FAO-pathway, F, by fatty acid, FA, in the presence of malate, M. Malate is a type N substrate (N), required for the F-pathway. The FA concentration has to be optimized to saturate the F-pathway, without inhibiting or uncoupling respiration. & NADH-linked substrates (type N-pathway to Q).
  • Respiratory stimulation by simultaneous action of the F-pathway and N-pathway with convergent electron flow in the FN-pathway for evaluation of an additive or inhibitory effect of F.
  • OXPHOS capacity P (with saturating [ADP]), active OXPHOS state.
4S OctGMSP FNS CETF&CI&II 1OctM;2D;3G;4S
5Rot SP S CII 1OctM;2D;3G;4S;5Rot
6Omy SL S CII 1OctM;2D;3G;4S;5Rot;6Omy
7U SE S CII 1OctM;2D;3G;4S;5Rot;6Omy;7U
8Ama ROX 1OctM;2D;3G;4S;5Rot;6Omy;7U;8Ama
  • Rox is the residual oxygen consumption in the ROX state, due to oxidative side reactions, estimated after addition of antimycin A (inhibitor of CIII). Rox is subtracted from oxygen flux as a baseline for all respiratory states, to obtain mitochondrial respiration (mt).


Questions.jpg


Click to expand or collaps
Bioblast links: SUIT protocols - >>>>>>> - Click on [Expand] or [Collapse] - >>>>>>>